2 results
Approved WMOCompleted
This is an exploratory study to assess changes in colonic inflammation after 8 weeks of treatment with tofacitinib (XELJANZ) 2 x 5 mg BID in patients with moderate to severely active UC.
Approved WMOCompleted
To study whether hyqvia is as effective, safe and tolerable (or more tolerable) as IVIg.